ERBB2 and breast carcinoma: Of these, 23% expressed HER2 at 45–480 times greater than the normal level; this high overexpression was associated with a poor clinical outcome, therefore the serum HER2 expression level may be useful to predict a poor clinical outcome in patients with HER2-positive breast cancer.